Charles River Laboratories International Inc
NYSE:CRL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
178.58
273.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Charles River Laboratories International Inc
Charles River Laboratories International Inc
Total Assets
Charles River Laboratories International Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Charles River Laboratories International Inc
NYSE:CRL
|
Total Assets
$8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Assets
$100.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Assets
$80.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Total Assets
$3.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Assets
$11.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Assets
$27.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
Charles River Laboratories International Inc
Glance View
Nestled within the intricate maze of the global life sciences sector, Charles River Laboratories International Inc. stands as a pivotal player. With a legacy dating back to 1947, the company has carved out a niche in providing essential research models and preclinical services that underpin crucial drug development processes. Its journey began by breeding laboratory animals, an unassuming yet vital task that feeds the robust pipeline of scientific inquiry and pharmaceutical innovation. This foundational service, involving the provision of research models such as rats and mice, forms the bedrock upon which the company built its expansive portfolio. It primes the pumps of early-stage research for pharmaceutical and biotechnology firms, offering a reliable source of high-quality, disease-specific models that are indispensable for preclinical trials. Today, Charles River Laboratories has evolved into a comprehensive partner for the biomedical and pharmaceutical industries. It derives its revenue by encompassing a broad portfolio of offerings beyond animal models, venturing into the vast domain of comprehensive drug discovery and safety testing for new pharmaceuticals. This makes the company instrumental in speeding up the development pipeline—from concept to the cusp of clinical trials. By providing everything from lab services, safety assessments, and manufacturing support, Charles River facilitates the journey of a drug from an embryonic idea to a tangible, market-ready solution, all while ensuring compliance with strict regulatory standards. This integration across verticals not only enriches its value proposition but ensures a steady stream of revenue across various stages of the drug development lifecycle.
See Also
What is Charles River Laboratories International Inc's Total Assets?
Total Assets
8B
USD
Based on the financial report for Sep 28, 2024, Charles River Laboratories International Inc's Total Assets amounts to 8B USD.
What is Charles River Laboratories International Inc's Total Assets growth rate?
Total Assets CAGR 10Y
16%
Over the last year, the Total Assets growth was 5%. The average annual Total Assets growth rates for Charles River Laboratories International Inc have been 4% over the past three years , 12% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
